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Abstract: The present study defined a simplified physiologically based pharmacokinetic 
(PBPK)  model  for  nicotine  and  its  primary  metabolite  cotinine  in  humans,  based  on 
metabolic  parameters  determined  in  vitro  using  relevant  liver  microsomes,  coefficients 
derived in silico, physiological parameters derived from the literature, and an established 
rat  PBPK  model.  The  model  consists  of  an  absorption  compartment,  a  metabolizing 
compartment, and a central compartment for nicotine and three equivalent compartments 
for  cotinine.  Evaluation  of  a  rat  model  was  performed  by  making  comparisons  with 
predicted  concentrations  in  blood  and  in  vivo  experimental  pharmacokinetic  values 
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obtained from rats after oral treatment with nicotine (1.0 mg/kg, a no-observed-adverse-
effect level) for 14 days. Elimination rates of nicotine in vitro were established from data 
from  rat  liver  microsomes  and  from  human  pooled  liver  microsomes.  Human 
biomonitoring data (17 ng nicotine and 150 ng cotinine per mL plasma 1 h after smoking) 
from pooled five male  Japanese smokers  (daily intake of 43 mg nicotine by smoking) 
revealed that these blood concentrations could be calculated using a human PBPK model. 
These results indicate that a simplified PBPK model for nicotine/cotinine is useful for a 
forward dosimetry approach in humans and for estimating blood concentrations of other 
related compounds resulting from exposure to low chemical doses. 
Keywords:  physiologically  based  biokinetic  modeling;  cytochrome  P450;  simulation;  
no-observed-adverse-effect level; biomonitoring; human liver microsomes 
 
1. Introduction 
It has been argued internationally that appropriate use of human biomonitoring information should 
be made in risk assessments when creating public policy [1,2] Development and dissemination of 
chemical-specific methods and basic information is necessary to interpret biomonitoring results and to 
promote  risk-based  decision  making  [3,4].  It  is  of  global  interest  to  develop  more  advanced  and 
accurate risk assessment systems to support appropriate interpretation and communication based on 
human biomonitoring results [5]. Pharmacokinetic and/or toxicokinetic parameters for a variety of 
chemicals have been determined in animal toxicology studies, even when limited corresponding data 
exist  for  humans  [6].  Species  differences  of  drug-metabolizing  enzymes  in  the  liver,  including 
cytochrome P450 enzymes, are the focus for understanding qualitative and quantitative differences in 
blood  concentrations  or  chemical  exposures  in  animals  and  in  humans  [7].  It  has  been  generally 
attempted to collect extensive information regarding specific physiologically based pharmacokinetic 
(PBPK)  models  found  in  the  literature  for  predicting  concentrations  in  various  biological  fluids 
following multiple dose exposures [4]. However, although simple, inexpensive, and reliable methods 
are  needed  for  evaluating  the  accurate  toxic  risk,  as  only  very  complicated  models  have  been 
established so far [8]. 
Conventional smoking  and environmental tobacco smoke have significant health  effects [9-12]. 
Levels of cotinine, a metabolite of nicotine [13-15], in the blood track exposure to tobacco smoke [9]. 
In the past 15 years, it has been reported that blood cotinine levels for nonsmokers in the United States 
population  have  decreased  by  about  70%,  indicating  that  public  health  interventions  to  reduce 
exposure have been successful (http://www.cdc.gov/exposurereport/), but such information for other 
groups or countries is limited [16,17]. Recently we reported that the biomonitoring of cotinine in urine 
was  a  good,  easy-to-use  marker  for  plasma  levels  of  the  sum  of  nicotine  metabolites  in Japanese 
smokers, independent of genetic polymorphism of the nicotine-metabolizing enzyme, P450 2A6 [18]. 
Therefore, the purpose of the present study was to carry out a forward dosimetry approach (shown 
in Figure 1), using data from chemical doses administered to animals to predict their concentrations in 
humans. As test substances, nicotine and its primary metabolite cotinine were selected because as Int. J. Environ. Res. Public Health 2010, 7                 
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mentioned, they are widely used as biomarkers for tobacco smoke, in spite of the complex metabolic 
fate of nicotine [19,20]. We report herein that the adjusted animal biomonitoring equivalents after 
orally administered doses at a no-observed-adverse-effect level (NOAEL) in rat studies were scaled to 
human biomonitoring equivalents using known species allometric scaling factors and human metabolic 
data with a simple PBPK model. A typical study of the biomonitoring of nicotine and cotinine in the a 
representative  pooled  blood  of  Japanese  smokers  [18]  supported  the  PBPK  model  used  in  the  
present study. 
Figure 1. Approach for calculating blood-based biomonitoring equivalents for nicotine. 
PK, pharmacokinetics. Biomonitoring of nicotine and cotinine in plasma was carried out in 
male Japanese smokers. 
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2. Experimental Section 
2.1. Chemicals, Animals, and Enzyme Preparations 
Nicotine and cotinine were obtained from Wako Pure Chemicals (Osaka, Japan). Male rats (7 weeks 
old) were treated daily with nicotine (1.0 mg/kg body weight) orally for 14 days or interperitoneally 
for  3  days,  based  on  a  NOAEL  dose  [21].  This  study  was  approved  by  the  experimental  animal 
committee of Showa Pharmaceutical University. Liver microsomes from male Sprague-Dawley rats (7 
weeks old) treated with nicotine (1.0 mg/kg) and from untreated controls were prepared as described 
previously  [22].  Microsomal  P450  contents  were  determined  spectrally  by  the  established  method 
[23,24]. Protein concentrations were measured by using a bicinchoninic acid (BCA) protein assay kit 
(Pierce,  Rockford,  IL,  USA).  Pooled  liver  microsomes  from  humans  were  obtained  from  BD 
Biosciences (Woburn, MA, USA). Typical P450 substrates, their reaction products, and other reagents Int. J. Environ. Res. Public Health 2010, 7                 
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used in this study were obtained from the sources described previously or were of the highest quality 
commercially available [22,25].  
Typical P450-dependent marker oxidation activities were measured in liver microsomes in rats to 
evaluate  enzyme  inductions  on  treatment  with  nicotine.  Activities  for  the  O-dealkylation  of 
ethoxyresorufin (20 µM, for P450 1A) and pentoxyresorufin (100 µM, P450 2B) and for testosterone 
7α-hydroxylation  (200  µM,  P450  2A),  tolbutamide  methyl  hydroxylation  (1,000  µM,  P450  2C), 
bufuralol 1′-hydroxylation (20 µM, P450 2D), chlorzoxazone 6-hydroxylation (50 µM, P450 2E), and 
midazolam 1′- and 4-hydroxylation (100 µM, P450 3A) were assayed according to the described high 
performance liquid chromatography methods [22,26,27]. 
2.2. Nicotine and Cotinine Determinations in Biological Samples from Rats and Human Smokers 
This  study  was  approved  by  the  ethics  committee  of  Showa  Pharmaceutical  University.  Blood  
and urine samples from individual rats and pooled human plasma from five male Japanese smokers  
(22–44 years old [18]) were diluted 10-fold with water. Nicotine and cotinine concentrations in these 
samples  were  measured  by  a  liquid  chromatography/mass  spectrometry  (LC/MS)  system  [28].  A 
Quattro micro API mass analyzer (Waters, Tokyo, Japan) was operated in the electrospray positive 
ionization mode and was directly coupled to a Waters LC 2695 system with an octadecylislane C18 
column  (Atlantis,  3  µm,  2.1  mm  ×  100  mm)  and  MassLynx  NT4.1  software  for  data  acquisition 
(Waters). To tune the mass spectrometer, the cone voltage was optimized to maximize the intensity of 
the precursor ions for nicotine (m/z = 163) and cotinine (m/z = 177). The collision energy was then 
adjusted  to  optimize  the  signal.  Typical  tuning  conditions  were  as  follow:  electrospray  capillary 
voltage, 3.2 kV; sample cone voltage for nicotine and cotinine, 28 and 38 V; and collision energy, 19 
and 23 eV, respectively, at a collision gas (Ar) pressure of 1.6 × 10
–4 kPa. The gradient mobile phase 
consisted of 50 mM ammonium formate (pH 5.0) and CH3CN (v/v): 0–3 min with 5% CH3CN (v/v)  
in 50 mM ammonium formate; for 3–8 min with 5%–30% CH3CN (v/v); for 8–11 min with 30% 
CH3CN; and for 11–18 min with 30%–5% CH3CN (v/v), at a flow rate of 0.25 mL min
–1. 
2.3. Human Metabolic Study 
Elimination rates of nicotine in liver microsomes from humans and rats in the presence of cytosolic 
fractions  were  measured  by  the  LC/MS  system  mentioned  above  and  were  compared.  Briefly,  
a  typical  incubation  mixture  consisted  of  100  mM  potassium  phosphate  buffer  (pH  7.4),  an  
NADPH-generating system, a substrate (1.0 µM), and liver microsomes (0.50 mg protein/mL) and 
cytosol (0.70 mg protein/mL, to yield cotinine, [29]) in a final volume of 0.25 mL. Incubations were 
carried out at 37 ºC for 30 min. The assay linearity with respect to time and protein concentration and 
the reproducibility (within <15%) were confirmed. The incubation was terminated by adding 0.40 mL 
of ice-cold acetonitrile.  
2.4. Estimation of Nicotine/Cotinine Concentrations by PBPK Modeling with Suitable Parameters 
A simplified PBPK model was set up as described previously [30,31]. Parameter values for the 
physicochemical properties of compounds (fu,p , logP, Kp,h, and Rb) are shown in Table 1. Values of fu,p Int. J. Environ. Res. Public Health 2010, 7                 
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and logP were obtained by in silico estimation using SimCYP and ChemDrawBioUltra software [32]; 
Kp,h was estimated from these two values (Appendix A), and Rb was assumed to be 1.0 (blood and 
plasma concentrations are assumed to be equal). Parameter values which represent the physiological 
properties  such  as  hepatic  volumes  and  blood  flow  rate  in  rats  or  humans  were  taken  from  the  
literature  [30].  Experimental  plasma  concentrations  of  compounds  were  analyzed  by  WinNonlin 
software (Professional version 5.01) with a one-compartment model and yielded primary ka and kel 
values as pharmacokinetic parameters (abbreviations used are also shown in Table 1). Values of total 
clearance (CLtot), hepatic clearance (CLh), CLh,int, and V1 were also calculated from the results of  
one-compartmental model (Appendix B). Subsequently, final parameter values (ka, CLh,int and V1) for 
the rat PBPK model were calculated using the initial values mentioned above by the user model in 
WinNonlin and are shown in Table 1. Consequently, the following systems of differential equations 
were solved to conduct the concentrations in each compartment shown in Figure 2. 
Table 1. Parameters used for the rat PBPK model. 
Parameter  Symbol  Nicotine  Cotinine  Unit 
Octanol-water partition coefficient  
Hepatic intrinsic clearance 
Liver-plasma concentration ratio 
Renal clearance 
Plasma unbound fraction 
Ratio of the blood to plasma concentration 
Volume of systemic circulation 
Hepatic volume 
Hepatic blood flow rate of systemic circulation  
to the tissue compartment 
Absorption rate constant 
Fraction absorbed × intestinal availability 
Dose 
logP 
CLh,int 
Kp,h 
CLr 
fu,p 
Rb 
V1 
Vh 
Qh 
 
ka 
FaFg 
Dose 
0.930 
5.44 
0.797 
0.0994 
0.688 
1.00 
0.746 
0.00850 
0.853 
 
1.07 
1.00 
0.25 
0.040 
0.208 
0.680 
0.00421 
0.743 
1.00 
0.451 
0.00850 
0.853 
 
- 
- 
- 
 
L/h 
- 
L/h 
- 
- 
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where Xg is the substance amount in gut, Ch is the hepatic substance concentration, and Cb is the blood 
substance concentration. 
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For cotinine: 
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Figure 2. PBPK model established in this study for rats and humans. 
FaFg ka
Dose (nicotine, p.o. administration)
Central compartment
V1, Cb
Nicotine
Qh
Cotinine
Central compartment
V1, Cb
Liver compartment
Vh, Ch
Liver compartment
Vh, Ch
Gut compartment
Xg
CLｒ ｒ ｒ ｒ CLｒ ｒ ｒ ｒ
CLh,int CLh,int
 
 
To define a simplified PBPK model for nicotine and cotinine in humans based on the rat PBPK 
model, we used relevant liver microsomes and physiological parameters (CLr, ka, and V1) and applied 
the systems approach to fit them into the traditional parallelogram (animal scale up strategy) for risk 
assessment [4], as shown in Figure 1 (Appendix C). The in vivo hepatic intrinsic clearance (CLh,int) of 
nicotine in humans was estimated by multiplying the calculated initial parameters for in vitro hepatic 
intrinsic clearance values in humans by the ratio of in vivo to in vitro hepatic intrinsic clearance in rats, 
as mentioned above for modeling in rats. Then, the final parameters for PBPK modeling in humans 
were calculated are shown in Table 2. As was done for the rat model, systems of differential equations 
were solved to achieve concentrations in each compartment in humans. 
Table 2. Parameters used for the human PBPK model. 
Parameter  Symbol  Nicotine  Cotinine  Unit 
Hepatic intrinsic clearance 
Renal clearance 
Volume of systemic circulation 
Hepatic volume 
Hepatic blood flow rate systemic circulation  
to the tissue compartment 
Absorption rate constant 
Dose 
CLh,int 
CLr 
V1 
Vh 
Qh 
 
ka 
Dose 
755 
4.25 
209 
1.50 
96.6 
 
0.795 
70 
20.6 
0.180 
127 
1.50 
96.6 
 
- 
- 
L/h 
L/h 
L 
L 
L/h 
 
h
–1 
mg 
Other parameters are the same as those shown in Table 1 for the rat PBPK model. Int. J. Environ. Res. Public Health 2010, 7                 
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3. Results and Discussion 
To obtain detailed PBPK model parameters, male rats were orally treated with nicotine according to 
the  protocol  for  general  repeated  exposure  tests.  Figure  3  shows  the  mean  levels  of  nicotine  and 
cotinine in blood and urine from rats after the final treatment of 14 daily repeated doses of nicotine 
(1.0 mg/kg). Nicotine was rapidly absorbed and immediately cleared within a half day (Figure 3A). 
Nicotine was extensively biotransformed to cotinine; cotinine elimination from the blood seemed to be 
slower  than  that  of  nicotine  (Figure  3B).  Urinary  excretion  of  nicotine  and  cotinine  was  almost 
complete within 24 h after the final repeated administration (Figures 3C, 3D). Renal clearance (CLr) 
values  of  nicotine  and  cotinine  were  calculated  from  the  amounts  excreted  into  the  urine  
(5.32 and 8.23 µg) divided by the area under the blood curves (56.5 and 1,970 µg·h/L), giving 0.0994 
and 0.00421 L/h, respectively. Primary hepatic clearance values of nicotine and cotinine were obtained 
by subtraction of CLr from total clearance. Values of the plasma unbound fraction (fu,p) of nicotine and 
cotinine were calculated to be 0.688 and 0.743, respectively, by in silico estimation with SimCYP 
(Table 1). 
Figure 3. PK profiles in rats treated with nicotine. Nicotine (A, C) and cotinine (B, D) 
concentrations  in  blood  (A,  B)  and  urine  (C,  D)  were  determined  in  rats  treated  with 
nicotine (1 mg/kg/day) after the final administration of 14 daily doses. 
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P450 induction in rat liver microsomes was investigated after intraperitoneal treatment with nicotine 
for 3 days (Figure 4). Judging from the typical P450-dependent drug oxidation activities, CYP2B- and 
CYP2C-mediated activities were slightly increased and decreased, respectively (Figure 4) as similarly 
described [33,34], suggesting that P450 induction or suppression by repeated treatments with nicotine 
was almost negligible in nicotine metabolism mediated mainly by several common and uncommon 
P450 isoforms in rats and humans. Consequently, final parameters such as hepatic intrinsic clearance Int. J. Environ. Res. Public Health 2010, 7                 
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(CLh,int), volume of systemic circulation (V1), and absorption rate constant (ka) for the rat PBPK model 
were recalculated from the primary values by the user-model in WinNonlin to give 5.44 L/h, 0.746 L, 
and 1.07 h
–1 and are shown in Table 1. By running the rat PBPK model system shown in Figure 2, the 
blood concentration curves of nicotine and cotinine were estimated after repeated oral administration 
with 0.25 mg of nicotine to a rat (250 g bw); the curves are shown in Figure 5. These estimated  
in  silico  concentration  curves  of  nicotine  and  cotinine  are  shown  with  the  experimental  in  vivo  
data points. 
Figure  4.  Liver microsomal P450-dependent activities after nicotine treatment. Control 
activities were taken from liver microsomes from untreated rats. Data columns with bars 
present means ± SDs (n = 4). Significant differences compared with the control activities: 
*p < 0.05.  
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Figure 5. Measured and estimated blood concentrations in rats after oral administration of 
nicotine (A) and cotinine (B) for 14 days. Data points with bars represent means ± SDs  
(n = 5). The curves show the concentrations estimated by PBPK modeling. 
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It has been reported that the ratios of in vitro over in vivo intrinsic clearance values have little 
species differences [35]. Hepatic clearance of nicotine in vitro was determined in pooled human liver Int. J. Environ. Res. Public Health 2010, 7                 
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microsomes and compared with data from liver microsomes from rats pretreated with nicotine and 
from  untreated  controls  (Table  3).  Hepatic  clearance  of  nicotine  in  human  liver  microsomes  was 
calculated  to  be  6.7  µL/min/mg  protein;  this  was  similar  to  the  values  obtained  for  rat  livers. 
Subsequently, hepatic intrinsic clearance of nicotine was found to be 24 L/h in an in vitro study using 
the biological coefficients already established. The intrinsic clearance values of nicotine based on rat  
in vivo (Table 1) and rat in vitro (Table 3) experiments were different; this ratio (5.44/0.173) was used 
as the compensating factor for estimating in vivo hepatic intrinsic clearance in humans. Finally, a value 
of 755 L/h for the nicotine hepatic intrinsic clearance (CLh,int) was adopted to represent the in vivo 
status in the final human PBPK model, the parameters of which are shown in Table 2. It should be 
mentioned that extensive hepatic clearance of nicotine assumed to be almost equal to and dependent on 
hepatic blood flow rate. 
Table 3. In vitro hepatic intrinsic clearance of nicotine determined using liver microsomes. 
Enzyme source 
Clearance, 
µL/min/mg protein 
L/h 
a 
Rat livers, untreated
 a 
Rat livers, treated with nicotine 
b 
Pooled human livers 
7.9 ± 1.4 
9.6 ± 1.9 
6.7 
0.142 
0.173 
24.0 
Nicotine  (1.0  µM)  was  incubated  with  rat  or  human  liver  microsomes  in  the  presence  of  an  
NADPH-generating system. The reduction rates of nicotine were determined by LC/MS. 
a Estimated clearance values were extrapolated using the following values: 40 mg liver microsomal 
protein per g liver, 10 g liver weight per 0.25 kg of rat body weight, and 1.5 kg liver per 70 kg of 
human body weight.  
b Mean ± SD (n =4) values using liver microsomes from individual rats pretreated with nicotine 
(1.0 mg/kg) daily for 3 days or from untreated controls. 
 
Figure 6 indicates the estimated human blood concentrations of nicotine and cotinine after modeling 
single  and  repeated  oral  administration  with  nicotine  (1.0  mg/kg).  The  apparent  maximum 
concentrations  of  nicotine  and  cotinine  were  estimated  to  be  approximately  20  and  180  ng/mL, 
respectively.  Our  estimated  CLtot  values  for  nicotine  in  rats  and  humans  were  calculated  to  
be 2.8 L/h/kg in rats and 81.5 L/h in humans, respectively, which were consistent with the reported 
CLtot values of 3.0 L/h/mg [36] in rats and 79.1 L/h [37] in humans. When daily administration of 
nicotine was modeled for 14 days, some accumulation of cotinine (approximately 20 ng/mL) was 
estimated by the present human PBPK model.  
Five  male  Japanese  smokers  provided  information  on  the  numbers  of  cigarettes  smoked  daily  
(mean, 31.0) [8]; using a value of 1.4 mg nicotine intake per cigarette [38], the estimated daily nicotine 
intake was 43.4 mg. This was one of the repetitive pooled samples for biomonitoring of plasma levels 
of nicotine and cotinine conducted after daily cigarette smoking in a population of 92 male Japanese 
smokers with a mean age of 37 years who had smoked an average of 23 cigarettes per day for 16 years 
[8]. Nicotine and cotinine concentrations in the pooled plasma samples taken from five smokers 1 h 
after smoking were 15.6 and 110 ng/mL, respectively. When the intake of 43.4 mg nicotine (as one 
dose) through the absorption compartment was modeled in a person with a body weight of 70 kg, the Int. J. Environ. Res. Public Health 2010, 7                 
 
 
3415
estimated concentrations of nicotine and cotinine in the central compartment after 1 h from the human 
PBPK model were 17 and 150 ng/mL, respectively, which fell within the ranges shown in Figure 6. 
Figure 6. Nicotine (A, C) and cotinine (B, D) concentrations modeled in humans after 
single (A, B) or multiple (C, D) oral administration of nicotine (1 mg/kg/day) estimated 
using the PBPK model. Only limited accumulation was observed for multiple doses. 
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It is generally accepted that PBPK modeling could be of use for understanding the relationship 
between  chemical  exposure  and  concentrations  in  body  fluids  (Figure  1).  However,  the  multiple 
compartments  and  many  complicated  equations  found  in  traditional  PBPK  modeling  cause  severe 
difficulties when applying the model. Simple and reliable methods have not yet been established, but 
such  models  are  needed  to  explore  the  biological  significance  of  a  wide  range  of  chemicals.  The 
present  study  defined  a  simplified  PBPK  model  for  nicotine  and  cotinine  in  humans  (Figure  2);  
the  model  was  based  on  physiological  parameters  derived  from  the  literature,  coefficients  derived  
in  silico,  metabolic  parameters  determined  in  vitro  using  relevant  liver  microsomes,  and  in  vivo  
experiment-supported PBPK modeling in rats (Figure 5). The developed PBPK model for nicotine and 
cotinine  in  rats  simply  consisted  of  three  compartments,  including  the  gut  as  a  chemical  receptor 
compartment  the  liver  as  a  metabolizing  compartment,  and  the  general  circulation  as  central 
compartment for nicotine, and three equivalent compartments for cotinine (Figure 2). In the present 
model (Figure 2), chemicals are received first at the receptor compartment with the net absorption 
factor as 1 (namely, FaFg = 1 indicating no first pass effects). Although the apparent gap between the 
oral and pulmonary uptake models might be problematic, chemical concentrations rapid absorbed from Int. J. Environ. Res. Public Health 2010, 7                 
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inhalation  route  [39]  could  be  treated  in  the  similar  PBPK  modeling  system.  Furthermore,  oral 
administration of chemicals is a key route of exposures based on the toxicology testing.  
Human biomonitoring is important for many aspects of environmental health [1,2]. Recently, the 
Centers for Disease Control and Prevention in the United State reported several pieces of relevant data, 
including  the  95th  percentile  values  of  serum  cotinine  levels  (~2  ng/mL,  http://www.cdc.gov/ 
exposurereport/). Human biomonitoring data presented in the current study using pooled plasma from 
male  Japanese  smokers  revealed  that  plasma  concentrations  of  nicotine  and  cotinine  could  be 
calculated using the developed PBPK model in humans (Figure 6). In our preliminary study, cotinine 
was detected in some plasma samples obtained from several male Japanese nonsmokers, resulting in 
approximately one cigarette equivalent per day among a one-third nonsmokers. Similarly, based on our 
forward dosimetry approach system, in the United States, nonsmokers (including children) receive the 
equivalent in nicotine of less than one cigarette per day as a result of exposure to second-hand smoke.  
Evaluation  of  the  developed  rat  model  was  performed  by  comparing  the  blood  concentrations 
predicted by PBPK modeling in silico and experimental pharmacokinetic values from plasma and urine 
obtained from rats in vivo after repeated oral treatment with nicotine at a no-observed-adverse-effect 
level.  In  the  present  study,  nicotine  metabolism  and  disposition  in  rats  was  similar  to  reported  
findings [36] by single intra-arterial treatment. To overcome the species differences in animals and 
humans, the traditional parallelogram technique used in systems biology [3,4] was adapted for this 
study to estimate the value of in vivo human hepatic clearance from in vitro data (Table 3). 
4. Conclusions 
The simplified PBPK model of nicotine and cotinine, especially in the context of biomonitoring for 
nicotine exposure, was developed and validated with a combination of algorithms, in vitro and in vivo 
experimentation and literature resources. In summary, the present study indicates that simplified PBPK 
modeling for nicotine and cotinine is useful for a forward dosimetry approach in rats and humans to 
estimate blood concentrations of nicotine and other related compounds from low chemical doses such 
as those at the no-observed-adverse-effect level. 
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Appendix A 
The liver-plasma concentration ratio (Kp,H) was calculated from Equation A1 [40]: 
h u,
p u,
, 960581 . 0 00396 . 0
72621 . 0 02289 . 0
f
f
P
P
K h p ×
+ ×
+ ×
=   (A1)  
where P is the water-octanol partition ratio and was estimated from the computer-calculated logP as 
neutral (clogP): 
P P
log 10 =   (A2)  
u,h f  is the hepatic unbound fraction for a specific binding on albumin, globulins, and lipoproteins. The 
tissue  interstitial  fluid-to-plasma  concentration  ratios  of  albumin,  globulins,  and  lipoproteins  were 
assumed to be 0.5: 
( ) 1 5 . 0 p u,
h u,
p u, + × = f
f
f
  (A3)  
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Appendix B 
The initial parameter values of CLh,int′ and V1′ used to execute the fitting calculation of the PBPK 
model with WinNonlin software were derived from the follow equations.  
 
Hepatic clearance (CLh) was estimated from Equation B1, which was derived from Equation B2: 
Dose Q AUC
Q CL AUC Q Dose
CL
h
h r h
h + ×
× × − ×
=   (B1)  
AUC
Dose
Q
CL
CL CL
F
CL
h
h
r h tot =
−
+
=
1
 
(B2)  
where AUC is the area under the curve.  
The bioavailability (F), fraction absorbed (Fa), and intestinal availability (Fg) are related as: 
h g a F F F F × × =   (B3)  
where Fh is fraction unmetabolized in the liver. 
In this study, we assume 0 . 1 = g aF F ; then, the bioavailability was calculated from Equation B4.  
(The prime represents the value under the assumption of 0 . 1 = g aF F ): 
h
h
h h g a Q
CL
F F F F F − = = × = ′ 1   (B4)  
The initial value of V1 was estimated from Equation B5 using the fitted calculation results of the  
one-compartment model (Vd/F) and the F′ value from Equation B4: 
( ) F F V V d ′ × = ′ / 1   (B5)  
The initial value of hepatic intrinsic clearance (CLh,int) was estimated from Equation B6, where CLh 
was evaluated from Equations B7,8:  
h h
h h
p u
b
h CL Q
CL Q
f
R
CL
−
×
× = ′
,
,int   (B6)  
( ) F K F V CL el d tot ′ × × = /  
(B7)  
r tot h CL CL CL − =  
(B8)  
Values of adjusted distribution volume (Vd/F) and elimination constant (Kel) were calculated from 
the fitting calculation of the one-compartment model, and Equation B7 was derived from Equation B9: 
( ) el d
tot K F V
F
CL
× = /   (B9)  
The initial value of ka for the fitting calculation was used as the primary results of WinNonlin with 
the one-compartmental model. 
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Appendix C 
The  parameter  values  of  CLr,  ka,  and  V1  in  the  human  PBPK  model  were  estimated  using  a  
scale-up strategy from rats to humans as follows. Human renal clearance CLr,human was estimated from  
Equation C1, which was derived from Equation C2, where  rat BW = 0.25 kg and human BW = 70 kg: 
3
2
3 / 2
,
, human
rat
rat r
human r BW
BW
CL
CL × =   (C1)  
3
2
BW a CLr × =   (C2)  
The human systemic circulation volume (V1,human) was estimated from Equations C3 and C4, where 
Vh,human, blood volume (Vb,rat), and Vb,human were 1.5 L, 0.016 L, and 4.9 L, respectively:  
b
h h p
human h human d human R
F K
V V V
×
× − =
,
, , , 1   (C3)  
( )
human b
human p u
rat p u
rat b
rat b rat d human b human d R
f
f
R
V V V V
,
, ,
, ,
,
, , , , × × − + =   (C4)  
where physicochemical parameters such as Kp,h, Rb, and fu,p were assumed to be consistent between 
rats and humans The derivation of Kp,h is shown in Appendix A. 
The human absorption rate constant (ka) was estimated from Equation C5 [41]: 
rat a human a k k , , 744 . 0 × =   (C5)  
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